echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NICE: It is recommended to combine Kisqali (ribociclib) with Fulvestrant for the treatment of locally advanced or metastatic breast cancer

    NICE: It is recommended to combine Kisqali (ribociclib) with Fulvestrant for the treatment of locally advanced or metastatic breast cancer

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In Europe, breast cancer is the most common cancer among women, the most common cause of death among Hispanic women, and the second most common cause of death among women of other races (after lung cancer).


    Breast cancer

    The National Institute of Health and Care Excellence (NICE) recommends Novartis's Kisqali routinely in some patients with advanced breast cancer.


    Since 2019, Kisqali been through cancer drug fund provided to patients will (CDF), while collecting more evidence to resolve the uncertainty about how much overall survival and cost-effectiveness of the drug may be extended.


    The fund NICE said in a statement that new evidence shows that fulvestrant combined with Kisqali treatment can significantly extend the life of breast cancer patients compared to fulvestrant alone.


     

    Original source:

    Original source:

    http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.